Cagrilintide vs Cerebrolysin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Cerebrolysin |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. |
| Best For |